Swedish Orphan Biovitrum AB (publ) (Sobi™) has released the company's 2020 Annual and Sustainability Report. The integrated report summarises our business and strategy, financial performance and work on sustainability.
"In 2020, we continued to take major steps in the transformation of the company and expanded beyond our traditional stronghold in haemophilia. We achieved solid growth during the year, and broadened the foundation of the company to align with our ambition of becoming a global leader in rare disease," said Guido Oelkers, CEO and President.
Sobi's 2020 Annual and Sustainability Report is available on sobi.com.
About Sobi™
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Sobi employs approximately 1,500 people across Europe, North America, the Middle East, Russia and Asia. In 2020, Sobi's revenues amounted to SEK 15.3 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at sobi.com.
For more information, please contact
Paula Treutiger, Head of Communication & Investor Relations
+ 46 733 666 599
[email protected]
Maria Kruse, Corporate Communication & Investor Relations
+ 46 767 248 830
[email protected]
Swedish Orphan Biovitrum AB (publ)
Postal address SE-112 76 Stockholm, Sweden
Phone: 46 8 697 20 00 www.sobi.com
We are a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases.
Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care.
We contribute to societies by improving access to treatment of rare diseases.
Every day, we work actively to find better ways to understand and meet patient needs.
Find out more about our business and financial performance.
Here we present our most recent press releases, news articles, and images.